Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › mosunetuzumab

mosunetuzumab

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of mosunetuzumab

3 trials tracked of mosunetuzumab.

3Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 2 Phase 1 1
  1. Phase 2 A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma Completed
  2. Phase 2 Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma Completed
  3. Phase 1 A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Mosunetuzumab plus polatuzumab vedotin achieved a 100% overall response rate in Japanese patients with LBCL
Hematology RCT
Mosunetuzumab plus polatuzumab vedotin achieved a 100% overall response rate in Japanese patients with LBCL Trial shows promising results for relapsed large B-cell lymphoma
This Phase III randomized controlled trial analyzed a subgroup of 16 Japanese patients with relapsed or refractory large B-cell lymphoma. Th…
A new treatment combination showed a high response rate and longer progression-free survival for patients with a specific type of lymphoma.
Aug 2, 2026
Fixed-duration subcutaneous mosunetuzumab shows favorable efficacy and safety versus IV in relapsed follicular lymphoma
Hematology Phase II
Fixed-duration subcutaneous mosunetuzumab shows favorable efficacy and safety versus IV in relapsed follicular lymphoma Subcutaneous Mosunetuzumab Shows Promise for Follicular Lymphoma Patients
This Phase 2 primary analysis evaluated fixed-duration subcutaneous mosunetuzumab versus mosunetuzumab IV in patients with relapsed or refra…
A Phase 2 trial found subcutaneous mosunetuzumab had lower rates of severe side effects than the IV version for treating follicular lymphoma…
May 1, 2026